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Sweet syndrome is still unknown; however, it is presumed to be a type
of hypersensitivity reaction that leads to stimulation of a cascade of
cytokines that precipitate neutrophil activation and infiltration.5
That is why corticosteroids and immunosuppressants have been
successfully used as treatments.6 We chose a nonsteroidal anti-
inflammatory agent over a corticosteroid or immunosuppressant.
The most frequent conditions associated with Sweet syndrome
are inflammatory bowel disease and hematopoietic neoplasm.5 A
work-up revealed that the patient did not have these diseases.
Cardiovascular involvement in Sweet syndrome is not so common.
There are a few reports of cardiovascular involvement in patients
with Sweet syndrome.7 Hayashi and associates8 reported a female
patient with Sweet syndrome who underwent aortic and mitral
valve replacement; this patient’s native valves showed no neutro-
phil infiltration. Similarly, no inflammatory cells had infiltrated
either the capsule or thrombus of our patient. We cannot find any
definite relationship between LV thrombus and Sweet syndrome,
and therefore we suggest that this is a case in which LV thrombus
and Sweet syndrome simply coincided.
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Apolipoprotein E4 increases aortic atheroma burden in cardiac surgical
patients
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The increasing numbers of elderly patients undergoingcardiac surgery emphasizes the importance of identify-ing risk factors associated with adverse neurologic out-comes. Although the apolipoprotein 4 allele
(APOE*E4) has been identified as a risk factor,1 how its presence
increases neurologic risk remains uncertain. Apolipoprotein E
(ApoE) plays a key role in lipoprotein metabolism and has an
important influence on the pathophysiology of atherosclerosis.
ApoE’s 3 major alleles (APOE*E2, APOE*E3, and APOE*E4)
result in differing susceptibility to dyslipidemia, atherosclerosis,
and coronary heart disease. Therefore we sought to determine
whether the APOE*E4 allele influences aortic atheroma burden in
patients undergoing cardiac surgery.
Patients and Methods
With institutional review board approval, a comprehensive trans-
esophageal echocardiography examination was performed in 128
patients undergoing coronary artery bypass grafting surgery. For
analysis, a videotaped frame displaying the most diseased area in
each aortic segment was digitized. By tracing the outline of the
atheroma, the area subtended by the atheroma was estimated (area
of plaque). Similarly, the area of visualized aorta in the ascending
aorta and aortic arch was measured by tracing the visualized
segment of the aorta (Figure 1). The area of the visualized aorta in
the descending aorta was measured by estimating the angle ()
subtended by the vessel wall and calculated as a portion of a
circular or complete vessel ( r2  /360°; Figure 1). Atheroma
burden in each segment was then calculated as the percentage of
area of the visualized aorta containing atheroma. Genomic DNA
was used to determine APOE allele frequencies, as previously
described.2 Differences between patients with and without the
APOE*E4 allele were compared by using the Wilcoxon rank sum
test and the Fisher exact test. The association of atheroma burden
and genotype was investigated with multivariable linear regression
controlling for age, sex, and diabetes.
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Results
The APOE*E4 allele was present in 19% of the 128 patients
enrolled. The mean percentage atheroma was greatest in the de-
scending aorta (10.2%  8.9%) and least in the ascending aorta
(0.9% 1.8%). In both the ascending aorta and the aortic arch, the
atheroma burden was approximately 2 times greater in the
APOE*E4 group than in the non-APOE*E4 group (P  .08 and
P  .04, respectively; Figure 2). Multivariable analysis revealed
that the APOE*E4 allele was significantly associated with ather-
oma burden in the aortic arch (P  .046). The association between
atheroma burden and APOE*E4 trended toward significance in the
ascending aorta (P  .085) but not in the descending aorta (P 
.57). Age was also an important predictor of atherosclerosis both in
the aortic arch and the descending aorta.
Discussion
The severity of aortic atherosclerosis has important ramifications
on the neurologic outcome of patients undergoing cardiopulmo-
nary bypass because atherosclerosis of the aorta has been corre-
lated with an increased risk of stroke after cardiac surgery.3 Aortic
atherosclerosis might result in cerebral embolization of atheroma
debris during cannulation, crossclamping, or decannulation and
possibly as a result of a sandblasting effect from the high-velocity
jet exiting the aortic cannula. Our study shows that, indepen-
dent of age, sex, and diabetes, the APOE*E4 allele is associated
with a greater degree of atherosclerosis in the aortic arch. The
increased atheroma burden might be a mechanism by which
APOE*E4 contributes to postoperative adverse cerebral out-
comes.
Figure 1. Atheroma burden in each aortic segment was determined as the ratio of the atheroma area (A) to the total
area of the aortic segment visualized. For the descending aorta, where the entire circumference could not always
be visualized, the area of the visualized segment was adjusted according to the angle () subtended by that
segment. r, Aortic radius.
Figure 2. Bar graph with SE bars showing the influence of the APOE*E4 allele on atherosclerosis in each segment
of the thoracic aorta. The APOE*E4 allele was associated with a significantly greater atheroma burden in the aortic
arch. It was also associated with twice the atheroma burden in the ascending aorta, although this did not reach
significance.*P  .04.
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Unlike the ascending aorta and aortic arch, there was no asso-
ciation between the descending aorta and APOE*E4. Potential
reasons for this include the fact that the progression of atheroscle-
rosis in the aorta is influenced by the flow dynamics and wall shear
stress within the segments of the aorta.4 For example, the higher
ejection velocity in the ascending aorta might limit formation of
plaques in this region. More importantly, the influence of age on
atherosclerosis is very strong, with an incidence rising steadily
with age.5 Because patients undergoing cardiac surgery are in-
creasingly elderly, the effect of APOE*E4 might be masked by the
dominating influence of age on atherosclerosis, particularly in the
descending aorta.
Limitations to our study include the fact that our technique uses
a 2-dimensional, rather than 3-dimensional, image of a specific
aortic segment. Nevertheless, the percentage of atheroma method
that we used does at least account for total plaque area that can be
visualized. Finally, epiaortic imaging is a more sensitive measure
of assessing plaque in the ascending aorta, and it is possible that a
greater degree of atherosclerosis might have been detected, with its
use potentially improving the link between atheroma burden and
the APOE*E4 allele.
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Systemic allergic reaction to the percutaneous patent foramen ovale
occluder
Kazuaki Fukahara, MD,a Kazutomo Minami, MD,a Nils Reiss, MD,a Dieter Fassbender, MD,b and
Reiner Koerfer, MD,a Bad Oeynhausen, Germany
Transcatheter occlusion of an atrial septal defect or patentforamen ovale (PFO) has become an effective and lessinvasive alternative to cardiac surgery.1 A number ofcomplications have been recognized.2 However, hyper-
sensitivity or allergic reaction to the device itself has been not
reported.
We treated a patient who had a systemic allergic reaction to the
percutaneous PFO occluder. The case is described, and the thera-
peutic implication is discussed.
Clinical Summary
A 37-year-old woman with a PFO was admitted to our institution
for transcatheter occlusion of her PFO. She had an episode of
paradoxical cerebral embolism 1 year previously, and anticoagu-
lation therapy with phenprocoumon had been initiated. Despite
anticoagulation therapy, the patient had a transient ischemic attack
6 months before admission. She was offered the option of trans-
catheter occlusion of her PFO, and she agreed to the procedure.
The patient had slight exertional dyspnea (New York Heart Asso-
ciation class I-II) but had no body weight change or fever at the
time of admission.
Transvenous occlusion of the PFO was performed with a PFO-
Star device (Cardia Inc, Burnsville, Minn) by using a 30-mm
umbrella under transesophageal echocardiographic guidance. The
postinterventional studies showed that the position of the device
was satisfactory, and there was no residual shunt.
Two months after PFO occlusion, the patient began having
dyspnea, a temperature of 38°C, and dependent edema. Endocar-
ditis or infection of the device was suspected, and she was referred
back to our institution. Laboratory examination revealed a white
blood cell count of 8800 mg/dL (granulocytes, 51.9%; lympho-
cytes, 31.4%; monocytes, 9.8%; eosinophils, 5.7%; and basophils,
1.2%), a hemoglobin concentration of 14.5 g/dL, a hematocrit
level of 43.2%, a platelet count of 256,000/dL, and a C-reactive
protein concentration of 0.8 mg/dL; other biochemical indices
were within normal limits. Echocardiography with color Doppler
scanning showed no residual shunt, no findings suggestive of
intracardiac vegetation, and good cardiac function. Blood cultures
were performed several times, but each showed no growth. Her
history was significant for allergic reactions to some medications
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